Capecitabine

• CAT Number: A000833
• CAS Number: 154361-50-9
• Molecular Formula: C15H22FN3O6
• Molecular Weight: 359.4
• Purity: ≥95%
• Target: DNA Synthesis
• Solubility: >18mg/mL in DMSO
• Storage: -20°C
• InChI: InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
• InChIKey: GAGWJHPBXLXJQN-UORFTKCHSA-N
• SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O

Capecitabine is a fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.

Reference

1: Hefner J, Berberich S, Lanvers E, Sanning M, Steimer AK, Kunzmann V. New
insights into frequency and contents of fear of cancer progression/recurrence
(FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral
capecitabine: a pilot study at a comprehensive cancer center. Patient Prefer
Adherence. 2017 Nov 14;11:1907-1914. doi: 10.2147/PPA.S142784. eCollection 2017.
PubMed PMID: 29180853; PubMed Central PMCID: PMC5694194.

2: Kobuchi S, Yazaki Y, Ito Y, Sakaeda T. Circadian variations in the
pharmacokinetics of capecitabine and its metabolites in rats. Eur J Pharm Sci.
2017 Nov 23. pii: S0928-0987(17)30650-4. doi: 10.1016/j.ejps.2017.11.021. [Epub
ahead of print] PubMed PMID: 29175408.

3: Upadhyay M, Adena SKR, Vardhan H, Pandey S, Mishra B. Development and
optimization of locust bean gum and sodium alginate interpenetrating polymeric
network of capecitabine. Drug Dev Ind Pharm. 2017 Nov 21:1-11. doi:
10.1080/03639045.2017.1402921. [Epub ahead of print] PubMed PMID: 29161913.

4: Hattori M, Ishiguro H, Masuda N, Yoshimura A, Ohtani S, Yasojima H, Morita S,
Ohno S, Iwata H. Correction to: Phase I dose-finding study of eribulin and
capecitabine for metastatic breast cancer: JBCRG-18 cape study. Breast Cancer.
2017 Nov 20. doi: 10.1007/s12282-017-0815-7. [Epub ahead of print] PubMed PMID:
29159517.

5: Araujo-Mino EP, Patt YZ, Murray-Krezan C, Hanson JA, Bansal P, Liem BJ, Rajput
A, Fekrazad MH, Heywood G, Lee FC. Phase II Trial Using a Combination of
Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly
Diagnosed Resectable Rectal Cancer. Oncologist. 2017 Nov 20. pii:
theoncologist.2017-0474. doi: 10.1634/theoncologist.2017-0474. [Epub ahead of
print] PubMed PMID: 29158365.

6: Sürmelioğlu N, Paydaş S, Karataş Y, Seydaoğlu G. Evaluation of lipid profiles
in patients treated with capecitabine. Turk J Med Sci. 2017 Aug
23;47(4):1206-1209. doi: 10.3906/sag-1607-53. PubMed PMID: 29156864.

7: McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders
CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC. A Phase I Trial of the
PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic
Breast Cancer. Clin Breast Cancer. 2017 Oct 28. pii: S1526-8209(17)30313-0. doi:
10.1016/j.clbc.2017.10.014. [Epub ahead of print] PubMed PMID: 29153866.

8: Cornejo-Uixeda S, Escoin-Pérez C, Hernandez-Lorente E. Capecitabine induced
pancreatitits. Med Clin (Barc). 2017 Nov 14. pii: S0025-7753(17)30778-9. doi:
10.1016/j.medcli.2017.10.004. [Epub ahead of print] English, Spanish. PubMed
PMID: 29150119.

9: Jiang Y, He Q, Li S, Shi C, Yang X. Reversible severe fatty liver induced by
capecitabine: A case report. Medicine (Baltimore). 2017 Nov;96(46):e8547. doi:
10.1097/MD.0000000000008547. PubMed PMID: 29145260.

10: Godinho J, Casa-Nova M, Mesquita T, Baptista MJ, Araújo F, Vale J, Passos
Coelho JL. Acute reversible toxic encephalopathy during capecitabine and
oxaliplatin treatment. J Oncol Pharm Pract. 2017 Jan 1:1078155217739686. doi:
10.1177/1078155217739686. [Epub ahead of print] PubMed PMID: 29121830.